Zacks: Analysts Expect Fate Therapeutics, Inc. (NASDAQ:FATE) Will Post Quarterly Sales of $13.12 Million

Analysts expect Fate Therapeutics, Inc. (NASDAQ:FATEGet Rating) to announce $13.12 million in sales for the current quarter, Zacks reports. Ten analysts have made estimates for Fate Therapeutics’ earnings, with the highest sales estimate coming in at $20.00 million and the lowest estimate coming in at $4.00 million. Fate Therapeutics posted sales of $13.41 million during the same quarter last year, which would indicate a negative year over year growth rate of 2.2%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Fate Therapeutics will report full year sales of $56.81 million for the current fiscal year, with estimates ranging from $30.00 million to $78.41 million. For the next year, analysts forecast that the company will post sales of $74.48 million, with estimates ranging from $27.51 million to $172.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Fate Therapeutics.

Fate Therapeutics (NASDAQ:FATEGet Rating) last issued its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.08. The company had revenue of $18.40 million for the quarter, compared to the consensus estimate of $9.01 million. Fate Therapeutics had a negative net margin of 368.76% and a negative return on equity of 34.89%. The firm’s revenue for the quarter was up 65.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.48) earnings per share.

A number of brokerages recently issued reports on FATE. StockNews.com upgraded Fate Therapeutics to a “sell” rating in a report on Thursday, March 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Fate Therapeutics in a research note on Friday, April 1st. Truist Financial dropped their price target on Fate Therapeutics from $125.00 to $75.00 in a research note on Wednesday, April 13th. Wedbush boosted their price objective on shares of Fate Therapeutics from $74.00 to $77.00 and gave the company an “outperform” rating in a research report on Tuesday, March 1st. Finally, HC Wainwright dropped their target price on shares of Fate Therapeutics from $122.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, March 4th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $87.22.

In other Fate Therapeutics news, CEO J Scott Wolchko sold 30,000 shares of the company’s stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $35.00, for a total transaction of $1,050,000.00. Following the transaction, the chief executive officer now owns 431,546 shares in the company, valued at approximately $15,104,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel Cindy Tahl sold 25,000 shares of the firm’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $38.85, for a total transaction of $971,250.00. Following the sale, the general counsel now directly owns 189,151 shares in the company, valued at approximately $7,348,516.35. The disclosure for this sale can be found here. Over the last three months, insiders sold 90,624 shares of company stock worth $3,270,224. Insiders own 18.58% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Exchange Traded Concepts LLC raised its stake in Fate Therapeutics by 21.1% during the 4th quarter. Exchange Traded Concepts LLC now owns 29,799 shares of the biopharmaceutical company’s stock valued at $1,744,000 after buying an additional 5,201 shares during the last quarter. Parametrica Management Ltd purchased a new stake in Fate Therapeutics during the third quarter valued at $1,180,000. Victory Capital Management Inc. lifted its holdings in Fate Therapeutics by 4.7% in the fourth quarter. Victory Capital Management Inc. now owns 955,312 shares of the biopharmaceutical company’s stock valued at $55,895,000 after acquiring an additional 43,132 shares during the period. Cubist Systematic Strategies LLC boosted its position in Fate Therapeutics by 331.1% in the third quarter. Cubist Systematic Strategies LLC now owns 81,034 shares of the biopharmaceutical company’s stock worth $4,803,000 after purchasing an additional 62,238 shares during the last quarter. Finally, Voya Investment Management LLC grew its stake in shares of Fate Therapeutics by 14.6% during the 3rd quarter. Voya Investment Management LLC now owns 239,875 shares of the biopharmaceutical company’s stock valued at $14,217,000 after purchasing an additional 30,588 shares during the period.

FATE stock opened at $21.83 on Thursday. The firm’s 50-day moving average price is $33.55 and its two-hundred day moving average price is $42.56. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -8.98 and a beta of 1.69. Fate Therapeutics has a 12-month low of $20.49 and a 12-month high of $97.43.

Fate Therapeutics Company Profile (Get Rating)

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.

Featured Stories

Get a free copy of the Zacks research report on Fate Therapeutics (FATE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.